Blueprint Medicines Corporation Stock News

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2021 Results - Earnings Call Transcript

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past year to ($1.72), which beat the

CAMBRIDGE, Mass., April 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2

CAMBRIDGE, Mass., April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

Blueprint Medicines is setting itself up to become the leader in precision oncology.

CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) pro

CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precis

CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera

CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the

The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.